此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

心脏结节病多中心前瞻性队列研究 (CHASM-CS)

2026年10月30日 更新者:Ottawa Heart Institute Research Corporation

Recent data has shown that sarcoidosis, presenting initially with cardiac manifestations (CS) of either conduction system disease or cardiomyopathy and sustained VT, is not uncommon. A Canadian physician survey found that most physicians do not investigate for CS as a possibility in these situations. Thus many patients with clinically important CS are going un-diagnosed. A study from Finland showed that missing the diagnosis of CS in these patients' leads to significant mortality and morbidity.

There are no published clinical consensus guidelines on treatment of CS. Corticosteroid therapy is advocated by most experts. This is based on very modest data from small retrospective observational studies using variable definitions of clinical response. The effect of corticosteroid treatment on the clinical course of CS has not been studied in prospective studies and will be one of the aims of this project. Recent physician surveys regarding CS, in Canada and the US, found that current clinical practice varies widely. The 2008 American College of Cardiology/American Heart Association/Heart Rhythm society guidelines recommend implantation of a defibrillator (Class IIa recommendation) to prevent sudden cardiac death. The most recent Canadian device therapy guidelines do not mention CS.

A multi-center collaborative approach to study CS is greatly needed." The investigators propose exactly that i.e. a multi-center prospective cohort to start to answer clinical questions. The investigators have formed the CANADIAN CARDIAC SARCOIDOSIS RESEARCH GROUP. The group includes respirologists with an interest in sarcoidosis, cardiac electrophysiologists, cardiac imaging specialists with extensive experience in imaging of sarcoidosis and biostatisticians. The research will be in two phases; a registry of current diagnostic approaches, treatment and prognosis, and a randomized clinical trial of the effect of corticosteroid treatment on the clinical course of cardiac sarcoidosis.

研究概览

地位

招聘中

详细说明

Baseline assessment of Clinically Manifest CS patients consists of: history, echocardiogram, ECG, chest CT scan, FDG-PET scan, blood for biomarkers within 2 months of the PET scan, cardiac MRI and possibly a signal average ECG and biopsy (encouraged-either endomyocardial or extra-cardiac).

Follow-up and clinical management of clinically manifest patients diagnosed with CS will occur at 3-6 months with a repeat FDG-PET scan and blood biomarkers. Follow-up will then be annually with an echo and ECG. Treatment with steroids/immunosuppressants and device therapy will be at the discretion of the treating physician.

Baseline assessment of patients diagnosed with extra-cardiac sarcoidosis and being screened for CS consists of: history, echocardiogram, ECG, holter, chest CT scan, biopsy, and cardiac MRI (CMR). If the CMR is suggestive of CS the patient will be have a FDG-PET scan done and be followed as a Clinically Silent patient. They will be contacted every 2 years. If the CMR is negative the patient will be followed as a extra-cardiac sarcoidosis patient with no evidence of CS and be in the control group. They will be contacted at 5 years and at the time of study completion.

All patients will be followed until the last patient recruited has been followed for 4 years.

The occurrence of the primary and secondary outcomes will be assessed in treated and untreated patients.

There will be 2 imaging core labs. The PET core lab will be located at UOHI under the direction of Dr. Robert Beanlands. The CMR core lab will be under the direction of Dr. Mathias Friedrich (McGill University). All scans will be read in the core labs by physicians who are blinded to the clinical details of the patients.

The Biomarker core lab will be at The University of Ottawa Heart Institute under the leadership of Dr P Liu.

研究类型

观察性的

注册 (估计的)

1500

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Janine E Ryan, BA(H), CCRP
  • 电话号码:17077 613-696-7000
  • 邮箱:jryan@ottawaheart.ca

研究联系人备份

学习地点

    • Alberta
      • Calgary、Alberta、加拿大、T2N 2T9
        • 招聘中
        • Libin Cardiovascular Institute of Alberta
        • 首席研究员:
          • Russell Quinn, MD
        • 接触:
          • Russell Quinn, MD
      • Edmonton、Alberta、加拿大、T6G 2B7
        • 招聘中
        • University of Alberta Hospital
        • 接触:
          • Tomascz Hruczkowski, MD
        • 首席研究员:
          • Tomascz Hruczkowski, MD
    • British Columbia
      • Vancouver、British Columbia、加拿大、V5Z 1M9
        • 招聘中
        • St. Paul's Hospital
        • 接触:
          • Shanta Chakrabarti, MD
        • 首席研究员:
          • Shanta Chakrabarti, MD
    • Nova Scotia
      • Halifax、Nova Scotia、加拿大、B3H 3A7
        • 招聘中
        • QEII Health Sciences Center
        • 首席研究员:
          • Ciorsti MacIntyre, MD
        • 接触:
          • Kim Anderson, MD
    • Ontario
      • Hamilton、Ontario、加拿大、L8L 2X2
        • 招聘中
        • Hamilton Health Sciences Centre
        • 首席研究员:
          • Jeff Healey, MD
        • 接触:
          • Gerard Cox, MD
        • 接触:
          • Jeff Healey, MD
      • London、Ontario、加拿大、N6A 5A5
        • 招聘中
        • London Health Sciences Centre
        • 接触:
          • Lorne Gula, MD
        • 首席研究员:
          • Lorne Gula, MD
      • Newmarket、Ontario、加拿大、L3Y 2P9
        • 招聘中
        • Southlake Regional Health Centre
        • 接触:
          • Bernice Tsang, MD
        • 首席研究员:
          • Bernice Tsang, MD
      • Ottawa、Ontario、加拿大、K1Y 4W7
        • 招聘中
        • University of Ottawa Heart Institute
        • 接触:
        • 首席研究员:
          • David Birnie, MD
        • 接触:
      • Toronto、Ontario、加拿大、M5G 2C4
        • 招聘中
        • Toronto General Hospital
        • 接触:
          • Andrew Ha, MD
        • 首席研究员:
          • Andrew Ha, MD
    • Quebec
      • Montreal、Quebec、加拿大、H1T 1C8
        • 招聘中
        • Montreal Heart Institute
        • 接触:
          • Lena Rivard, MD
        • 首席研究员:
          • Lena Rivard, MD
      • Montreal、Quebec、加拿大、H3G 1A4
        • 招聘中
        • McGill University Health Centre
        • 接触:
          • Fiorella Rafti
        • 首席研究员:
          • Martin L Bernier, MD
      • Montreal、Quebec、加拿大、H2W 1T8
        • 尚未招聘
        • Centre Hospitalier de l"Universite de Montreal-Hotel Dieu
        • 接触:
          • Julie Fleury, RN
        • 首席研究员:
          • Benoit Coutu, MD
    • Saskatchewan
      • Regina、Saskatchewan、加拿大、S4P 0W5
        • 招聘中
        • Prairie Vascular Research Inc-Regina General Hospital
        • 接触:
        • 首席研究员:
          • Andrea Lavoie, MD
      • Sapporo、日本、060-8638
        • 招聘中
        • Hokkaido University
        • 接触:
        • 首席研究员:
          • Ichizo Tsujino, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 99年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

概率样本

研究人群

Electrophysiology Service patients

描述

Inclusion Criteria:

To diagnose Clinically Manifest CS all following criteria must be met:

(i) Positive biopsy* for Sarcoid (either EMB or extra-cardiac) AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis AND (iii) one or more of the following clinical features:

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%) AND (iv) No alternative explanation for clinical features AND (v) FDG-PET suggestive of active CS

To diagnose clinically silent CS all of the following criteria must be met

(i) Biopsy proven extra-cardiac sarcoidosis

AND/OR (ii) CT Chest highly suggestive of pulmonary sarcoidosis

AND (iii) CMR suggestive of cardiac sarcoidosis

AND (iv) Does not have criteria for clinically manifest CS ie. should not have any of following

  • advanced conduction system disease (sustained Mobitz II AV block or third degree AV block)
  • non- sustained or sustained ventricular arrhythmia
  • ventricular dysfunction (LVEF < 50% and/or RVEF < 40%)

Patients with negative CMR will be designated as 'extra-cardiac sarcoidosis with no evidence of CS' and followed as control

Exclusion Criteria:

  • unable or unwilling to provide informed consent
  • patients who are pregnant or lactating
  • patients with known claustrophobia
  • age < 18 years

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
CS screened as underlying etiology
  1. Patients with active Clinically Manifest CS
  2. Patients diagnosed with extra-cardiac sarcoidosis and being screened for CS

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Primary Outcome for ALL Patients
大体时间:Through study completion, on average 10 years

The primary outcome is a composite of cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation.

Heart failure hospitalization is defined as admission to hospital > 24 hours and received treatment for heart failure.

Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

次要结果测量

结果测量
措施说明
大体时间
Secondary Outcomes for ALL Patients
大体时间:Through study completion, on average 10 years

1. Total mortality Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for ALL Patients
大体时间:Through study completion, on average 10 years

2. Individual components of primary outcome (cardiac death, aborted sudden cardiac death, sustained ventricular arrhythmia, heart failure hospitalization or cardiac transplantation) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years

1. Change in LVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years

2. Change in RVEF from baseline (%) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years

3. Change in cardiac disease activity from pre-treatment to on treatment and post-treatment cessation as assessed by FDG-PET Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years

4. Atrial fibrillation burden (from ICD and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years

5. Ventricular arrhythmia burden, including PVC burden (from ICD diagnostics and/or pacemaker diagnostics) Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years

6. Appropriate ICD therapy Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years

7. Percentage (%) of ventricular pacing Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Manifest Disease
大体时间:Through study completion, on average 10 years

8. AV nodal function Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years
Secondary Outcomes for Patients with Clinically Silent Disease and Control Patients
大体时间:Through study completion, on average 10 years

1. Development of Clinically Manifest CS Primary and secondary endpoints will be assessed at various time intervals to be decided.

Through study completion, on average 10 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Pablo Nery, MD、Ottawa Heart Institute Research Corporation
  • 首席研究员:Rob Beanlands, MD、Ottawa Heart Institute Research Corporation
  • 首席研究员:David Birnie, MD、Ottawa Heart Institute Research Corporation

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2012年8月1日

初级完成 (估计的)

2027年3月1日

研究完成 (估计的)

2035年12月1日

研究注册日期

首次提交

2011年11月10日

首先提交符合 QC 标准的

2011年11月18日

首次发布 (估计的)

2011年11月22日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年10月30日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅